Hepatitis C. Infection, transmission, recognition, and treatment.
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA.
J B
JB
Gross
D003131:Combined Modality Therapy; D006526:Hepatitis C / Q000175:diagnosis* / Q000628:therapy / Q000635:transmission; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D010348:Patient Care Team; D011320:Primary Health Care; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin